--- a
+++ b/clusters/3009knumclusters/clust_67.txt
@@ -0,0 +1,1051 @@
+Patients must have histologically or cytologically confirmed alveolar soft part sarcoma that is not curable by surgery; diagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is enrolled prior to patient enrollment
+Histologically- or cytologically-confirmed CRC that is metastatic
+Histologically confirmed diagnosis of adenocarcinoma of the rectum
+The patient must have histologically confirmed, gastric carcinoma, including gastroesophageal junction (GEJ) adenocarcinoma (patients with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the GEJ)
+Histologically or cytologically confirmed cholangiocarcinoma.
+Histologically or cytologically confirmed small cell lung cancer
+Patients must have pathologically/histologically confirmed tumor of non-small cell histology
+Patients must have unresectable or metastatic, histologically confirmed low or intermediate grade (Klimstra Criteria) pancreatic neuroendocrine tumor (PNET) with radiological evidence of disease progression since last treatment
+Patients must have a biopsy with histologically confirmed diagnosis of recurrent endometrial cancer confined to the pelvis and/or vagina and no evidence of extrapelvic disease
+Patients must have histologically or cytologically diagnosed advanced anaplastic thyroid cancer (ATC)
+COHORT B: Patients must have histologically or cytologically confirmed primary desmoplastic melanoma that is unresectable; patients in Cohort B must have measurable disease per RECIST 1.1
+Patients must have pathologically (histologically or cytologically) proven diagnosis of MCC by local pathology review
+Histologically confirmed diagnosis of WHO grade II meningioma confirmed by central pathology review prior to step 2 registration
+Histologically confirmed, new diagnosis of PTCL
+Histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ? 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67/MIB-1 is expressed in >50% of tumor cells.
+Participant must have histologically or cytologically confirmed small cell lung cancer and may not be a candidate for potentially curative therapy
+Subject has histologically confirmed diagnosis of GBM.
+Phase 1 ONLY: histologically or cytologically confirmed advanced/metastatic solid tumors for which carboplatin/etoposide treatment is considered appropriate.
+Histologically confirmed adenocarcinoma of the prostate
+Participants must have histologically confirmed melanoma that is metastatic or unresectable
+Histologically or cytologically confirmed prostate cancer
+Participants must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum
+Patients must have histologically or cytologically confirmed non-rhabdomyosarcoma of soft tissue or bone at any site
+Participants must have histologically or cytologically confirmed adenocarcinoma of the rectum
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Patients must have confirmed progression during or after treatment with either nivolumab or pembrolizumab. Confirmed progression is defined as:
+Histologically confirmed advanced malignant melanoma, regardless of subtype (for screening and treatment phases)
+Histologically confirmed metastatic colorectal cancer, not amenable to curative resection
+Have histologically or cytologically confirmed SCLC that meets:
+Histologically or cytologically confirmed GI malignancy for which mFOLFOX6 is considered an appropriate treatment (e.g., gastric cancer [GC], colorectal carcinoma, pancreatic adenocarcinoma)
+Have documented histologically or cytologically confirmed advanced NSCLC with no small cell histology or neuroendocrine histology
+Must have a confirmed diagnosis of active MM
+In dose expansion (part 2), patients must have histologically or cytologically confirmed unresectable or metastatic melanoma, renal cell carcinoma, ovarian cancer, or colorectal cancer
+Histologically confirmed or cytologically confirmed diagnosis of stage IV NSCLC
+Phase 1: Subjects must have a histologically or cytologically confirmed diagnosis of metastatic (AJCC stage IV) NSCLC that carries an ALK rearrangement with CNS metastases, as determined by FISH, RT-PCR, immunohistochemistry (IHC), or NGS via a CLIA-certified LDT
+Patients with histologically confirmed advanced solid tumors (regimen A) or breast or pancreas (regimen B)
+Histologically confirmed presence of BCG-unresponsive CIS (with or without Ta or T1 disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1 disease.
+Patients must have histologically confirmed MCM or ALM that is metastatic or unresectable
+INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Histologically confirmed metastatic adenocarcinoma of the pancreas
+INCLUSION CRITERIA FOR THIRD-LINE THERAPY: Histologically confirmed metastatic adenocarcinoma of the pancreas
+Histologically or cytologically confirmed Stage IIIb or IV non-small cell lung cancer HER2 IHC 2+ or 3+ by local laboratory assessment.
+Histologically or cytologically confirmed Stage IIIb or IV breast cancer with cutaneous metastases.
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
+Participants must have histologically or cytologically confirmed disease from any solid tumor
+Histologically or cytologically documented, injectable cancer lesion (limited to solid tumors and mycosis fungoides)
+Participants must have histologically or cytologically confirmed disease from any solid tumor
+COHORT D: Histologically confirmed diagnosis of melanoma
+Patient has histologically/cytologically confirmed, non-keratinizing/undifferentiated, EBV-related nasopharyngeal carcinoma, not amenable to curative intent therapy; EBV testing may be completed per institutional standards
+Participants with histologically or cytologically confirmed hormone receptor (HR)-positive, Her2-negative metastatic breast cancer; central confirmation of HR positivity is not required
+Participants must have histologically or cytologically confirmed low- to intermediate-grade neuroendocrine tumor (carcinoid tumor)
+Have a histologically-confirmed diagnosis of MB, NB, ES, or ARMS
+Part A and Part B: Has histologically or cytologically-confirmed metastatic solid tumor.
+Patients who have the below specified histologically or cytologically confirmed malignancies that have progressed to the advanced or metastatic stage.
+Histologically or cytologically confirmed diagnosis of metastatic medullary thyroid cancer
+Participant must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is metastatic or unresectable. Participants must have either progressed after receiving prior therapy for metastatic disease, or be ineligible for, or have refused all other currently available therapeutic options
+Histologically- or cytologically-confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the EGJ
+Histologically or cytologically confirmed diagnosis of melanoma.
+Histologically or cytologically-confirmed metastatic pancreatic ductal adenocarcinoma.
+Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment
+Histologically confirmed prostate cancer; small cell/neuroendocrine differentiated allowed but not required for study participation
+Patients must have persistent or recurrent histologically confirmed USC
+The diagnosis must be histologically confirmed by a gynecologic pathologist as containing >= 10% uterine papillary serous (UPSC) adenocarcinoma in the specimen
+Histologically or cytologically confirmed diagnosis of melanoma
+Histologically or cytologically confirmed adenocarcinoma of the prostate. No evidence of neuroendocrine differentiation or small cell features.
+Histologically confirmed adenocarcinoma of the breast
+Subject must have histologically-confirmed diagnosis of prostate adenocarcinoma and have received primary surgical management by radical prostatectomy
+Histologically or cytologically confirmed advanced (stage IIIB or IV) NSCLC
+Histologically confirmed prostate adenocarcinoma within 365 days prior to randomization.
+Histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy.
+Histologically or cytologically confirmed advanced solid tumors including:
+Patients must have histologically confirmed solid tumor that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefit.
+Participants must have histologically or cytologically confirmed stage IV invasive breast cancer. Participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
+Have previously untreated, histologically confirmed NSCLC and histologically confirmed Stage IIB or IIIA NSCLC.
+Participants must have histologically or cytologically confirmed stage IV uveal melanoma
+Histologically confirmed breast adenocarcinoma that is unresectable loco-regionally advanced or metastatic.
+Have histologically confirmed GBM
+Has a histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and have received, or been intolerant to, or been ineligible for all treatment known to confer clinical benefit. Participants with solid tumors of any type are eligible for enrollment.
+Histologically or cytologically confirmed limited or extensive disease stage of SCLC. The disease should be progressing during or relapsing after the previous treatment.
+Patient must have histologically or cytologically confirmed metastatic or recurrent NSCLC which is progressing.
+Primary operable, non-metastatic invasive carcinoma of the breast, confirmed histologically by core biopsy.
+Patients must have cytologically or histologically confirmed relapsed or refractory extensive-disease small-cell lung cancer (ES-SCLC) or non-progressing ES-SCLC after first line chemotherapy, or advanced or inoperable grade I-II pulmonary NETs
+Histologically confirmed diagnosis of GIST
+Histologically or cytologically confirmed, treatment-naive esophageal squamous cell carcinoma
+Measurable, histologically/cytologically confirmed metastatic colorectal cancer (mCRC).
+ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants must have histologically confirmed advanced NSCLC (with a confirmed KRAS mutation via any Clinical Laboratory Improvement Act [CLIA]-certified method) for which curable treatment modalities are not an option
+histologically confirmed diagnosis of metastatic CRPC
+Histologically confirmed adenocarcinoma of the prostate
+Patients with a histologically or cytologically confirmed solid tumor malignancy
+Histologically confirmed prostate adenocarcinoma
+Participants must have histologically confirmed adenoid cystic carcinoma with evidence of recurrent or metastatic disease not amenable to potentially curative surgery or radiotherapy
+Histologically or cytologically confirmed unresectable or medically inoperable malignant pleural mesothelioma
+Patients must have histologically confirmed solid tumor that is metastatic or unresectable, and there is no available therapy likely to convey clinical benefit
+Histologically or cytologically-confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is EGFR mutation positive; rare sensitizing mutations allowed
+Patients of any age must have histologically or cytologically confirmed embryonal or alveolar rhabdomyosarcoma (RMS) confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)
+Histologically confirmed GBM (WHO grade IV).
+Has a histologically- or cytologically-confirmed advanced/metastatic solid tumor or lymphoma by pathology report and who has received, or been intolerant to, all treatment known to confer clinical benefit. Solid tumors and lymphomas of any type are eligible for enrollment.
+Subjects with histologically or cytologically confirmed non-small cell lung cancer (NCSLC).
+New diagnosis of brain metastases from a histologically or cytologically confirmed primary or metastatic NSCLC tumor within 5 years of registration on the study. If the original histological proof of malignancy is greater than 5 years, then pathological confirmation is required (i.e.: from extra-cranial or intracranial disease).
+Histologically confirmed prostate adenocarcinoma
+Histologically or cytologically proven diagnosis of non-small cell lung cancer
+Must have histologically or cytologically confirmed advanced pancreatic ductal adenocarcinoma (PDAC) that is metastatic. The definitive diagnosis of metastatic PDAC will be made by integrating the histopathological data within the context of the clinical and radiographic data. Patients with islet cell neoplasms are excluded.
+Histologically or cytologically-documented, advanced solid tumor of one of the following types:
+Histologically-confirmed adenocarcinoma of the prostate
+Males diagnosed with histologically confirmed, adenocarcinoma of the prostate based on core biopsy prior to study entry from transrectal ultrasonography (TRUS)
+Histologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small-cell features
+Histologically or cytologically confirmed metastatic UM
+Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
+Participants must have histologically or cytologically confirmed invasive breast cancer
+Histologically confirmed lymphoma (WHO classification), or confirmed MM (IMWG), that is relapsed and/or refractory.
+Patients must have cytologically or histologically confirmed advanced NSCLC; patients with mixed histology containing a small cell lung cancer component are not eligible
+For enrollment into the MET cohort: participants must have a histologically or cytologically confirmed advanced non-small cell lung cancer (NSCLC) and must have received at least one prior line of therapy in the metastatic setting
+For enrollment into the NTRK cohort: participants must have a histologically or cytologically confirmed advanced solid tumor and must have received at least one prior line of therapy in the metastatic setting
+Diagnosed with histologically confirmed solid tumor located in the peripheral lung
+Histologically confirmed unresectable metastatic colorectal adenocarcinoma
+Histologically or cytologically confirmed diagnosis of an advanced, malignant, solid tumor(s) with all standard treatment options having been exhausted or declined.
+Have histologically or cytologically confirmed recurrent AML as defined by >= 5% myeloblasts by manual aspirate differential of bone marrow biopsy
+Histologically or cytologically confirmed non-small cell lung cancer, advanced, recurrent, or metastatic
+Must have immune checkpoint naïve histologically/cytologically confirmed advanced or metastatic CRC.
+Has histologically or cytologically confirmed triple negative breast carcinoma that is either metastatic (stage IV of the TNM classification) or locally recurrent and not amenable to local curative treatment.
+Histologically confirmed malignant/anaplastic meningioma, WHO grade III with any prior surgery
+Histologically or cytologically-proven non-small cell lung cancer (NSCLC)
+The patient has a histologically or cytologically confirmed metastatic pancreatic adenocarcinoma.
+Patients must have histologically confirmed unresectable NSCLC for which nivolumab is clinically appropriate. Patients must have had one line of prior therapy and have progressed or have discontinued due to toxicity.
+Histologically or cytologically confirmed AML according to the WHO classification
+Histologically or cytologically confirmed diagnosis of prostate cancer
+Histologically or cytologically confirmed diagnosis of advanced disease of any of the following tumor types:
+EXPANSION COHORT: Histologically or cytologically confirmed diagnosis of advanced pancreatic adenocarcinoma; \r\n* Maintenance group (n=10): Patients must be stable on front-line therapy (defined as at least 4 months stable disease on nab-paclitaxel + gemcitabine)\r\n* Second-line group (n=10): Patients must have failed or could not tolerate the front-line fluorouracil (5FU)-based therapy for advanced pancreatic cancer
+Confirmed diagnosis of CMML
+Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)
+Histologically or cytologically confirmed PSCC
+Subjects must have histologically confirmed solid malignancy that is metastatic or unresectable
+Histologically/cytologically confirmed advanced/metastatic or unresectable solid tumors, no treatment options
+Patients must have a histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic, unresectable, or recurrent
+Patients must have histologically or cytologically confirmed advanced or metastatic:
+Histologically confirmed colorectal adenocarcinoma
+PHASE I: Histologically confirmed solid tumor malignancy
+Histologically confirmed diagnosis of one of the following:
+Histologically or cytologically confirmed diagnosis of NSCLC that carries an ALK rearrangement
+Histologically confirmed adenocarcinoma of the prostate
+Stratum D: Patients must have a histologically confirmed diagnosis of ependymoma that is recurrent, progressive or refractory following therapy which included radiotherapy
+Stratum E: Patients must have a histologically confirmed diagnosis of medulloblastoma that is recurrent, progressive or refractory following therapy which included radiotherapy
+Histologically or cytologically confirmed non-squamous NSCLC
+Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma; patients without histologically confirmed adenocarcinoma may be eligible if both the treating physician and the study principal investigator (PI) agree that the patient’s history is unambiguously indicative of advanced adenocarcinoma
+Participants must have histologically confirmed malignant tumor
+Patient has definitive histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. Patients with islet cell or neuroendocrine neoplasms are excluded.
+Histologically confirmed CAH or grade 1 EC
+Subjects must have a histologically confirmed pancreatic adenocarcinoma that has had an R0 (negative margins) or R1 (microscopically positive margins) resection
+Patients must have histologically or cytologically confirmed metastatic or unresectable adenocarcinoma of the colon or rectum
+Patients must have histologically or cytologically documented advanced or metastatic adenocarcinoma of the pancreas
+Histologically confirmed prostate adenocarcinoma (within 365 days of randomization) at intermediate risk for reoccurrence determined by at least one of the following: Gleason Score 7, PSA > = 10 and < = 20, T stage T2b - T2c
+Histologically confirmed neurotropic primary melanoma
+Histologically confirmed prostate adenocarcinoma at the time of surgery
+Patients must have must have histologically or cytologically confirmed SCLC
+Patients must have histologically or cytologically malignant mesothelioma confirmed by the National Cancer Institute (NCI) Laboratory of Pathology. Patients with pleural, peritoneal, pericardial or tunica vaginalis mesothelioma are eligible
+Histologically or cytologically confirmed adenocarcinoma of the prostate and the availability archival prostate tumor sample is required
+Patients must have histologically or cytologically confirmed any solid tumor (cohort 1) or prostate cancer (cohort 2); no prior treatment other than testosterone lowering therapy for mCRPC is required
+Participants with histologically or cytologically confirmed diagnosis of adenocarcinoma of the GEJ or stomach will be enrolled in this study
+Histologically or cytologically confirmed hepatocellular carcinoma or biliary tract cancer.
+Histologically confirmed diagnosis of cHL.
+Patients who have histologically confirmed metastatic or unresectable GIST.
+Histologically proven adenocarcinoma of the prostate
+Documented histologically confirmed adenocarcinoma of the prostate
+Histologically confirmed diagnosis of supratentorial glioblastoma.
+Histologically or cytologically proven pancreatic adenocarcinoma (subjects with endocrine or acinar pancreatic carcinoma are not eligible)
+Histologically or cytologically confirmed metastatic or advanced inoperable diagnosis of non-small cell lung cancer (NSCLC)
+Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant
+Histologically confirmed metastatic adenocarcinoma of the prostate without histological neuroendocrine differentiation or small cell features
+Histologically confirmed adenocarcinoma of the prostate, who meet the following criteria:
+Histologically or cytologically confirmed adenocarcinoma of the colon or the rectum that is metastatic or unresectable.
+Histologically or cytologically confirmed non-small cell lung cancer, performed on a biopsy that occurred within the last 60 days
+Have a histologically confirmed advanced solid tumor for which curative treatment is not available
+Patients must have histologically or cytologically confirmed metastatic colorectal cancer.
+Histologically or cytologically confirmed diagnosis of early stage prostate cancer
+Have histologically or cytologically confirmed metastatic or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma
+Histologically confirmed adenocarcinoma of the prostate
+Histologically confirmed classical HCL by the enrolling institution
+Histologically or cytologically confirmed non-small cell lung cancer
+Histologically and cytologically documented diagnosis as gastroesophageal adenocarcinoma.
+Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed BRAFV600 wild-type melanoma
+Has histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features.
+Patients must have histologically confirmed new diagnosis of breast cancer
+Histologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is be excluded)
+Histologically or cytologically confirmed adenocarcinoma of prostate.
+Histologically or cytologically proven diagnosis of breast cancer with evidence of metastasis.
+Histologically or cytologically confirmed ovarian epithelial cancer
+Subjects must have histologically or cytologically confirmed advanced epithelial ovarian, fallopian tube, or primary peritoneal (>= International Federation of Gynecology and Obstetrics [FIGO] Stage IIIC)
+Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
+Histologically confirmed adenocarcinoma of the prostate without signet cell or small cell features
+Histologically or cytologically confirmed metastatic, non-squamous or squamous Non-Small Cell Lung Cancer (NSCLC)
+Histologically confirmed diagnosis of colorectal adenocarcinoma
+Histologically documented adenocarcinoma of the prostate
+Have a histologically confirmed diagnosis of NSCLC
+Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.
+Subjects must have histologically confirmed malignancy that is metastatic or unresectable and for which there is no available therapy likely to convey clinical benefit.
+Patients must have histologically and or cytologically confirmed metastatic colorectal cancer
+Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate with no histological variants (such as small cell, sarcomatoid, pure ductal cancer, transitional cell carcinoma).
+Patients with histologically or cytologically confirmed stage IV NSCLC not amendable to curative surgery or radiation
+Have histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma
+Histologically or cytologically confirmed prostate carcinoma.
+Histologically or cytologically-confirmed diagnosis of metastatic KRAS wildtype colorectal cancer (CRC)
+Histologically confirmed adenocarcinoma of the prostate (with previous diagnostic tissue available for tumor marker analysis)
+Histologically confirmed pancreatic adenocarcinoma with initial diagnosis within 6 weeks of consent
+Has histologically or cytologically documented adenocarcinoma NSCLC.
+Histologically documented adenocarcinoma of the prostate
+Have histologically or cytologically confirmed diagnosis of SCCHN irrespective of PD-L1 status, which is either inoperable and recurrent, or metastatic
+Patients must have histologically or cytologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma; histologic documentation (via the pathology report) of the original primary tumor is required
+Subjects with histologically confirmed metastatic or unresectable breast cancer
+Histologically or cytologically confirmed metastatic or unresectable CRC that is relapsed, refractory, or progressive following at least 2 prior systemic regimens in the metastatic setting.
+For all arms except Arm G, subjects must be refractory to, or intolerant of, established therapy known to provide clinical benefit for their conditions, or where subjects refuse existing therapies. For Arm G, subjects must have newly histologically or cytologically confirmed diagnosis of locally advanced cervical cancer confined to the pelvis only.
+Histologically or cytologically confirmed non-small cell lung cancer, performed on a biopsy that occurred within the last 120 days
+Confirmed or suspected diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC); for suspected NSCLC, diagnosis must be histologically or cytologically confirmed prior to start of nivolumab treatment; neuroendocrine cancers, or mixed neuroendocrine features in > 10% of tumor cells, are excluded
+Histologically or cytologically confirmed adenocarcinoma of the prostate.
+have a histologically confirmed diagnosis of ER+ breast cancer;
+Histologically or cytologically confirmed adenocarcinoma of the distal esophagus, gastroesophageal junction or stomach, including patients with HER2+ disease; distal esophagus is defined as within 5 centimeters of the gastroesophageal junction (GEJ)
+Histologically confirmed advanced TET (thymoma or thymic carcinoma)
+Patients must have histologically or cytologically confirmed non-mucinous, epithelial stage 3 or 4 carcinoma of the ovary, fallopian tube or peritoneum
+Histologically or cytologically confirmed solid tumor cancer
+Diagnosis of histologically confirmed invasive primary rectal carcinoma
+Histologically confirmed ductal carcinoma in situ (DCIS) or invasive breast cancer (stages I, II, or III) with primary tumor(s) >= 1.0 cm on mammogram, ultrasound, magnetic resonance imaging (MRI), or physical exam or histologically confirmed adenocarcinoma of the colon, stages I, II or III with primary tumor >= 1cm visualized by colonoscopy
+Participants must have histologically confirmed metastatic or unresectable melanoma
+Histologically or cytologically confirmed adenocarcinoma of the prostate without signet cell, or small cell features.
+Histologically proven invasive adenocarcinoma of breast
+Histologically confirmed malignancy of the bladder
+Histologically- or cytologically- confirmed CRC
+Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma; mixed histology will be included as long as the predominant histology is adenocarcinoma
+Subjects must have histologically or cytologically confirmed metastatic triple negative breast cancer
+Histologically or cytologically confirmed, previously treated, locally-advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) or other CA19-9 positive malignancies
+Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma that has progressed on one or more chemotherapy regimens.
+Participants must have histologically or cytologically confirmed adenocarcinoma of colorectal or pancreatic origin
+Must have a histologically or cytologically confirmed, incurable malignancy, for which further standard treatment is not currently available.
+Patients must have histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert I-III) adenocarcinoma confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)
+Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate;
+Histologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as documented via CT scan (within 6 weeks of Screening);
+Histologically or cytologically proven adenocarcinoma of the pancreas
+Histologically or cytologically confirmed recurrent non-small cell lung cancer not amenable to curative intent therapy or stage IV NSCLC
+Histologically confirmed colorectal cancer
+Documented histologically confirmed adenocarcinoma of the prostate
+Histologically confirmed FL.
+Histologically confirmed high grade astrocytoma
+Subjects must have histologically or cytologically confirmed adenocarcinoma of the prostate
+Subject has predominant histologically or cytologically confirmed neuroendocrine prostate cancer (mixed histology is permissible, as is positivity of serum CgA and CEA)
+Patient has histologically or cytologically confirmed non-small cell lung cancer not amenable to curative intent therapy or stage IV NSCLC
+Histologically or cytologically confirmed TNBC based on the most recent analyzed biopsy or other pathology specimen. TNBC determination as per local institution as per standard guidelines.
+Histologically confirmed cancers for which no curative therapy exists.
+Histologically or cytologically confirmed hematologic malignancy
+Patients must have histologically or cytologically confirmed epithelial endometrial carcinoma; all histologies are accepted; patients with diagnosis of endometrial carcinosarcoma will be enrolled in the exploratory cohort (arm C) and will receive combination of cabozantinib and nivolumab
+Histologically confirmed diagnosis of RCC
+Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable or metastatic disease
+Subject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease
+Subjects with histologically or cytologically confirmed extensive stage disease SCLC
+Histologically or cytologically confirmed malignant secretory or non-secretory pheochromocytoma or paraganglioma that is unresectable and deemed inappropriate for alternative local regional therapeutic approaches
+Histologically documented adenocarcinoma of the prostate
+Histologically confirmed prostate cancer of any stage undergoing RP
+Histologically confirmed adenocarcinoma of the small intestine that is advanced (not amenable to surgery) or metastatic (clinical stage IV); for the purposes of this study, ampullary tumors are considered a part of the duodenum and are classified as adenocarcinomas of the small intestine
+Histologically-confirmed adenocarcinoma of the prostate
+Participants must have histologically or cytologically confirmed carcinoma; central pathology review is not required; however, pathology will be reviewed at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins
+Patients must have histologically confirmed diagnosis of chordoma; the pathologic confirmation may be from another metastatic site
+Histologically confirmed stage 3A non-small cell lung cancer (NSCLC)
+Histologically confirmed mPAC (mixed histology is acceptable as long as the predominant histology is pancreatic adenocarcinoma)
+Patients with histologically or cytologically confirmed, resectable colon cancer and other resectable cancers without distant metastases, who are candidates for surgical resection of the tumor
+Histologically or cytologically confirmed diagnosis of advanced stage gastric, gastro-esophageal, or esophageal cancers in whom ramucirumab and paclitaxel are reasonable treatments
+Patients must have metastatic histologically or cytologically confirmed pancreatic adenocarcinoma or sarcoma (soft tissue or bone) for which progression was documented for at least one line of therapy
+Histologically (archival tissue) confirmed adenocarcinoma of the rectum that begins within 12 cm of the anal verge as determined by sigmoidoscopy and/or colonoscopy with no evidence of distant metastasis
+Patients must have histologically or cytologically confirmed prostate cancer (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaP
+Have histologically or cytologically confirmed diagnosis of pancreatic carcinoma
+Histologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is be excluded
+Histologically confirmed adenocarcinoma of the prostate (clinical stage T1c–T3b, N0, M0) without involvement of lymph nodes, bone, or visceral organs
+Have histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma based on pathology report
+Histologically or cytologically confirmed metastatic or locally advanced adenocarcinoma of the pancreas
+Patients must have histologically or cytologically confirmed solid organ malignancy
+Patients enrolled in the expansion cohort must have histologically or cytologically confirmed squamous non-small cell lung cancer (NSCLC), breast or pancreaticobiliary tract cancer
+Histologically or cytopathologically confirmed adenocarcinoma of the pancreas
+PHASE II: Patients must have histologically or cytologically confirmed, PIK3CA mutant metastatic colorectal cancer; PIK3CA status must be confirmed by tumor sequencing conducted in a Clinical Laboratory Improvement Act (CLIA) certified lab
+Documented histologically confirmed adenocarcinoma of the prostate
+Histologically confirmed prostate adenocarcinoma
+Histologically confirmed primary non-metastatic adenocarcinoma of the prostate
+Histologically or cytologically confirmed HNSCC of the oral cavity (OC; more than 90% patients have HPV negative cancer) or oropharynx (about 60-80% of patient have HPV positive cancer)
+Histologically confirmed adenocarcinoma of the breast that is Her2 negative (by DAKO Herceptest, fluorescence in situ hybridization [FISH], or other approved assay)
+Histologically cytologically confirmed NSCLC
+Histologically confirmed recurrent, advanced or metastatic pancreatic ductal adenocarcinoma as determined by National Cancer Institute (NCI) Laboratory of Pathology
+Patients must have histologically or cytologically confirmed cancer of prostate (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaP
+Patients must be diagnosed with relapse of previously histologically confirmed PFEPN
+Histologically or cytologically confirmed small cell lung cancer (SCLC)
+Patients with a histologically confirmed or presumed diagnosis of gynecologic malignancy for whom chemotherapy with paclitaxel and carboplatin is planned
+Subjects with histologically confirmed metastatic breast cancer that is either TNBC or HR-positive
+Patients must have histologically or cytologically confirmed progressive advanced or metastatic solid tumor of one of the following:
+Histologically or cytologically confirmed adenocarcinoma involving the gastroesophageal junction or gastric cardia
+Histologically confirmed diagnosis of cluster of differentiation (CD)30-positive ALCL with documented ALK-positive status
+Documented histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed pleural malignant mesothelioma, epithelial or biphasic subtypes
+Histologically or cytologically confirmed malignant melanoma from skin, or mucosal melanoma (i.e. ocular melanoma subjects are not eligible)
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Patients must have histologically or cytologically confirmed small cell lung cancer
+Histologically confirmed diagnosis of colon or rectal adenocarcinoma of any clinical stage, previously untreated with chemotherapy or radiotherapy, with a plan to undergo surgical resection no sooner than 7 days from the projected date of study drug initiation
+Diagnosis of histologically or cytologically confirmed metastatic or non-resectable synovial sarcoma
+Patients with histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas
+Have histologically- or cytologically- confirmed unresectable or metastatic ACC that is considered incurable by local therapies
+Histologically confirmed epithelioid predominantly (> 70%) subtype malignant pleural mesothelioma
+Histologically confirmed CD20-positive DLBCL, any stage, bulky or nonbulky disease
+Histologically confirmed DLBCL (WHO classification).
+Patients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluation
+Histologically confirmed diagnosis of CD20 positive iNHL with histological subtype limited to:
+Patients with histologically confirmed KRAS positive metastatic colorectal cancer
+Patients must have histologically or cytologically confirmed malignant pleural mesothelioma (MPM)
+Have a histologically confirmed advanced solid tumor for which curative treatment is not available
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology)
+Histologically confirmed diagnosis of melanoma
+CAPMATINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
+CERITINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
+REGORAFENIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
+ENTRECTINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
+Histologically confirmed primary glioblastoma multiforme (GBM)
+Histologically or cytologically confirmed carcinoma of the prostate (excluding neuroendocrine differentiation or squamous cell histology)
+Histologically confirmed malignant extra-cranial solid tumor or desmoid fibromatosis.
+Histologically or cytologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction (EAC)
+Histologically or cytologically confirmed advanced (stage IIIB or IV) non-squamous, non-small cell lung cancer
+Histologically confirmed diagnosis of primary non small lung cancer (NSCLC) on predominantly non-squamous histology
+Histologically or cytologically confirmed diagnosis of NSCLC that is:
+Histologically or cytologically confirmed pancreas adenocarcinoma receiving initial chemotherapy for metastatic disease and without evidence of disease progression on treatment
+Advanced malignancies (except leukemias), histologically proven at diagnosis; Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS
+Histologically confirmed prostate cancer
+Patients with a histologically-confirmed, advanced solid malignancy for which pembrolizumab is approved (Parts C and D)
+Must have a confirmed diagnosis of active MM
+Histologically or cytologically confirmed advanced or metastatic RCC with clear cell component
+New diagnosis of histologically confirmed adenocarcinoma of the rectum
+ARM B COHORT 3: Patients must have a histologically confirmed diagnosis of non-small cell lung cancer
+PHASE I: Histologically confirmed advanced RCC of any subtype
+Histologically confirmed breast cancer
+Histologically confirmed diagnosis of adenocarcinoma of the prostate and most recent biopsy within 365 days of study enrollment
+Histologically-proven invasive adenocarcinoma of the pancreas
+Histologically or cytologically confirmed advanced solid tumor malignancy, refractory or relapsed from prior therapy, or for whom no alternative therapy is available
+Histologically or cytologically confirmed diagnosis of solid malignant tumor.
+Subjects must have histologically or cytologically confirmed adenocarcinoma of the pancreas
+Histologically or cytologically confirmed adenocarcinoma of the prostate (the availability archival prostate tumor sample is preferred not required)
+Patients must have histologically or cytologically confirmed at least 1 thyroid nodule that is >= 1 cm but =< 4 cm measured in greatest dimension and confirmed by the Laboratory of Pathology, National Cancer Institute (NCI) or confirmed by the pathology laboratory of enrolling institution:\r\n* Indeterminate thyroid biopsy per Bethesda System for reporting thyroid cytopathology with BRAF V600E mutation or RET/positron emission tomography (PET) rearrangement\r\n* Cytologically or histologically suspicious or confirmed PTC per Bethesda System for reporting thyroid cytopathology
+Histologically confirmed metastatic or recurrent HER2-negative (via IHC or FISH per ASCO/CAP guidelines 2013) breast cancer or histologically confirmed metastatic solid tumor
+Histologically confirmed cancer by a Mount Sinai pathologist
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically proven adenocarcinoma of the pancreas (within the last 90 days)
+Histologically confirmed diagnosis of cancer as per the cohort specifications
+Histologically confirmed primary non-metastatic adenocarcinoma of the prostate
+Histologically confirmed diagnosis of epithelial cancer; subject must have a measurable disease for enrollment consideration
+Patients with histologically or cytologically confirmed diagnosis of refractory metastatic solid tumor for whom no other standard treatment options are available
+Non-small cell lung cancer (NSCLC), histologically and/or cytologically proven
+Histologically or cytologically confirmed metastatic colorectal adenocarcinoma (colon, rectal, colorectal, appendiceal cancer) or small bowel that is not resectable
+Arm 1: histologically or cytologically confirmed solid tumors that are advanced that gemcitabine-based treatment is considered a clinically appropriate option
+Arm 2: histologically or cytologically confirmed adenocarcinoma of the pancreas that is locally advanced or metastatic
+Arm 3: histologically or cytologically confirmed solid tumors that are advanced that gemcitabine plus cisplatin treatment is considered a clinically appropriate option
+Histologically- or cytologically-confirmed CRC
+Histologically confirmed metastatic gastric or esophagogastric junction (type I, II, III Siewert) adenocarcinoma
+Patients with histologically or cytologically confirmed metastatic clear cell RCC who are eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy; diagnosis must be confirmed by pathologist review of screening biopsy; the determination of resectability will ultimately lie in the clinical judgment of the urologist and medical oncologist involved in the care of the patient
+Pathologically confirmed adenocarcinoma of the pancreas
+Patients must have a histologically confirmed diagnosis of adenocarcinoma of the prostate
+Histologically and/or cytologically confirmed adenocarcinoma of the pancreas, clinical stage T1-4, N0-1, M0
+Has a histologically- or cytologically-confirmed metastatic solid tumor for which there is no available therapy which may convey clinical benefit. Part E: Has advanced malignant melanoma.
+Histologically confirmed AML by hematopathology review performed within four weeks prior to study entry
+Histologically-confirmed adenocarcinoma of the prostate
+Histologically-confirmed primary uveal melanoma
+Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate
+Patients must have histologically or cytologically confirmed glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma
+Patients must have pathologically confirmed adenocarcinoma of the pancreas
+Have histologically proven adenocarcinoma of the colon or rectum
+Histologically confirmed diagnosis of adenocarcinoma of the prostate within one year of study entry; evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson
+Patients must have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy as follows:
+Histologically confirmed glioma
+Histologically or cytologically confirmed adenocarcinoma of the pancreas
+Histologically confirmed HER2-positive metastatic breast cancer
+Histologically confirmed adenocarcinoma of the rectum in patients with no prior therapy who are candidate for surgical resection
+All patients must have histologically confirmed prostate adenocarcinoma, with biopsies obtained within twelve months of patient registration
+Histologically confirmed non-small cell lung cancer (NSCLC)
+Histologically proven adenocarcinoma of the pancreas
+Histologically confirmed diagnosis of invasive cervical cancer
+Participants must have histologically confirmed primary cancer of the uterus or cervix with histologically confirmed metastasis to one or more parametrial, pelvic, or para-aortic nodes prior to enrollment; participants diagnosed at other institutions must have pathology reviewed and confirmed at Massachusetts General Hospital (MGH) or another Dana-Farber (DF)/Harvard Cancer Center (HCC) institution
+Phase Ib: Patient must have histologically or cytologically documented solid tumor malignancies
+Patient must have suspected intrahepatic or hilar cholangiocarcinoma with minimal extrahepatic disease; diagnosis must be histologically or cytologically confirmed for continued treatment on study after pump placement
+The diagnosis of GBM or anaplastic astrocytoma must be histologically confirmed
+Histologically confirmed diagnosis of chordoma or chondrosarcoma
+Participants with histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable disease
+Histologically confirmed diagnosis of prostate cancer.
+50% or less histologically or cytologically-proven ocular melanoma metastases in the parenchyma of the liver.
+Histologically or cytologically proven adenocarcinoma of the pancreas that has been resected with a close (< 2.5mm) or positive margin based on surgical and pathological findings
+Pathologically (histologically) proven diagnosis of prostatic adenocarcinoma
+All subjects must have history of histologically confirmed malignancy; brain biopsy is not required unless diagnosis is judged to be in doubt by the treating physician
+Histologically positive margins
+Histologically confirmed diagnosis of NSCLC
+Patients must have a histologically documented peritoneal carcinomatosis from either colorectal or appendiceal adenocarcinoma
+Histologically confirmed prostate adenocarcinoma within 365 days of registration
+Histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically documented disease
+Subject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma.
+Histologically confirmed adenocarcinoma of the prostate
+Pathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)
+Have histologically- or cytologically-confirmed diagnosis of Stage IV NSCLC and meet the corresponding requirements for the cohort of the study they will enroll into;
+Histologically or cytologically confirmed
+Histologically or cytologically confirmed (patients with mixed histologies are required to have a dominant transitional cell pattern.)
+Histologically confirmed invasive well-moderately differentiated rectal adenocarcinoma diagnosed within 90 days prior to enrollment.
+Patients must have histologically confirmed solid malignancy or lymphoma that is metastatic or unresectable
+Histologically or cytologically confirmed diagnosis of stage III/IV Non-Small Cell Lung Cancer (NSCLC)
+Histologically or cytologically confirmed metastatic or recurrent tumor types
+Histologically or cytologically confirmed advanced (unresectable and/or metastatic) HCC
+Histologically confirmed prostate cancer (not exclusive of adenocarcinoma)
+Histologically confirmed glioblastoma or gliosarcoma in 1st, 2nd or 3rd relapse.
+Cytologically or histologically confirmed non squamous NSCLC Stage IV (including pleural effusion).
+Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.
+Histologically or cytologically confirmed colorectal adenocarcinoma.
+Histologically or cytologically documented non-small cell lung cancer (NSCLC) .
+Histologically confirmed prostate cancer, currently with progressive disease
+Histologically or cytologically confirmed adenocarcinoma of the breast
+Histologically confirmed diagnosis of ACC according to Weiss system by a national reference pathologist who has to be nominated before study initiation.
+Patients must have histologically or cytologically confirmed malignant mesothelioma for which they have received pemetrexed in combination with cisplatin as part of chemotherapeutic regimen.
+Males with histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed solid tumors or hepatocellular carcinoma with known disease progression.
+Patients with histologically-confirmed Tis, T1a, or T4 tumors
+Histologically confirmed adenocarcinoma of the prostate without morphologic neuroendocrine differentiation or small cell features.
+Histologically- or cytologically-confirmed mCRC.
+Histologically confirmed advanced solid tumors with measurable lesions per RECIST v1.1 that are considered nonamenable to surgery or other curative treatments or procedures.
+Documented histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed diagnosis of Stage IV non-squamous NSCLC.
+Histologically or cytologically confirmed adenocarcinoma of the prostate (excluding predominant small cell histology)
+Histologically or cytologically confirmed BRAF- or MEK-mutated melanoma
+A histologically or cytologically confirmed diagnosis of stage IV NSCLC
+Histologically or cytologically confirmed colorectal adenocarcinoma
+Histologically confirmed diagnosis of a CD20+ B-cell malignancy;
+History of histologically confirmed, clinical localized adenocarcinoma of the prostate treated with radical prostatectomy with definitive intent
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed locally advanced or borderline resectable pancreatic ductal adenocarcinoma. Patients with clinical suspicion of pancreatic adenocarcinoma can be enrolled for pre-treatment biopsy, and must be histologically confirmed to have adenocarcinoma before being treated on study. Patients with squamous carcinoma, adenosquamous carcinoma or neuroendocrine tumor will be excluded
+Histologically confirmed unresectable metastatic colorectal adenocarcinoma
+Histologically-confirmed metastatic CRC
+Cytologically confirmed pancreatic adenocarcinoma
+Have histologically or cytologically confirmed non-small cell lung cancer
+Histologically-confirmed advanced or metastatic unresectable gastric carcinoma, or adenocarcinoma of the gastroesophageal junction
+Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with locally advanced or metastatic disease
+Patients must have histologically or cytologically confirmed carcinoma of the prostate (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaP
+Histologically or cytologically confirmed colorectal adenocarcinoma, with metastatic disease documented on diagnostic imaging studies
+Patients with histologically confirmed carcinoma of the female breast with any or unknown hormone receptors (HRs)/HER2 status
+Patients must have newly diagnosed (i.e., within 4 weeks), histologically or cytologically confirmed non-small cell lung cancer
+Histologically confirmed stage IV colorectal adenocarcinoma without any prior systemic treatment
+Patients must have histologically or cytologically confirmed metastatic urothelial carcinoma; urothelial cancer derived from the bladder, ureter or upper tract is permitted
+Histologically confirmed plasmacytoma amenable for biopsy
+Pathologically (histologically or cytologically) or radiographically-proven (based on the American Association for the Study of Liver Diseases [AALSD] criteria) unresectable or locally recurrent hepatocellular cancer prior to registration
+Part 2 patients must have histologically confirmed glioblastoma or gliosarcoma
+Histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically-confirmed diagnosis of HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx.
+Patients must have histologically-proven GBM
+Subjects with histologically confirmed diagnosis of recurrent germ cell tumor
+On primary diagnosis, patients must have had histologically confirmed adenocarcinoma of the colon or rectum; metastasis or recurrence do not need to be histologically confirmed
+Patients must have histologically and/or cytologically confirmed solid tumors or B cell lymphoma that are metastatic or unresectable and for which standard treatment options do not exist; patients with hepatocellular carcinoma are eligible without pathological diagnosis if diagnosed on the basis of blood work and imaging
+Histologically or cytologically confirmed advanced RCC with predominantly clear cell subtype
+Patients with histologically or cytologically confirmed metastatic NETs of any origin of low or intermediate grade (Part 1)
+Patients with histologically confirmed unresectable or metastatic pancreatic (p)NETs of low or intermediate grade; high-grade tumors or tumors with small cell histology will be excluded (Part 2)
+Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer with no prior systemic treatment
+Histologically confirmed high grade serous or endometrioid ovarian, peritoneal or fallopian tube malignancy that is metastatic and for which curative measures do not exist; pathology must be reviewed and confirmed at Mayo Clinic Department of Pathology; the histology can be confirmed from tissue that was taken at the time of diagnosis; a biopsy at the time of recurrence prior to enrollment on study is not required
+Histologically confirmed melanoma of cutaneous primary; metastatic melanoma from unknown primary are allowed
+In dose escalation, patients must have histologically or cytologically confirmed metastatic disease from any solid tumor; in dose expansion, patients must have histologically or cytologically confirmed metastatic melanoma, renal cell carcinoma, ovarian cancer, or colorectal cancer
+Histologically confirmed solid tumor (leukemia and lymphoma are excluded)
+Histologically proven GBM
+Subjects must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
+Histologically confirmed adenocarcinoma of the prostate (biopsy within one year of enrollment)
+Histologically confirmed adenocarcinoma of the prostate
+Histologically- or cytologically- confirmed solid tumor (except melanoma) that is\n             metastatic or unresectable
+Patients must have histologically confirmed glioblastoma that is progressive or recurrent following radiation therapy and temozolomide
+Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/ cholangiocarcinoma (including primary intra- and extrahepatic diseases); pathologic confirmation may be made from the primary or a metastatic site
+Have histologically proven adenocarcinoma of the pancreas; patients with mixed histology will be excluded
+Must have histologically confirmed diagnosis of MPNST
+Subjects must have histologically or cytologically confirmed previously treated unresectable mesothelin expressing advanced lung adenocarcinoma (stage IIIB or IV) as confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)
+Patients without histologically or cytologically confirmed node metastases or any other metastases
+Female with histologically confirmed breast cancer
+Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate
+PHASE II: Patients must have histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas with no prior systemic therapy for metastatic disease
+Patients must have histologically or cytologically confirmed non-central nervous system primary breast or non-small cell lung cancer
+Histologically documented diagnosis of pancreatic adenocarcinoma
+Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic or unresectable; in the dose expansion phase, the tumor must express AR by immunohistochemistry; if >= 1% of the tumor cells express AR, it will be considered positive for this trial
+Patients with a histologically-confirmed diagnosis of melanoma who have imaging findings suggestive of 1 to 4 brain metastases
+Study participants must have histologically or cytologically confirmed unresectable or metastatic malignant melanoma
+Histologically or cytologically proven diagnosis of adenocarcinoma of the pancreas prior to registration
+Histologically documented adenocarcinoma of the prostate
+Patients must have histologically or cytologically-confirmed pancreatic adenocarcinoma
+Cytologically or histologically confirmed pancreatic adenocarcinoma (excluding islet cell or ampullary tumors) that is metastatic or unresectable
+Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary appendiceal tumors
+Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary colorectal and appendiceal tumors
+Histologically confirmed metastatic adenocarcinoma of the lung
+Patient must have histologically or cytologically confirmed diagnosis of malignant pleural mesothelioma; surgical resection must not be planned
+Histologically documented adenocarcinoma of the prostate
+The diagnosis must be histologically confirmed by a gynecologic pathologist as containing >= 10% UPSC adenocarcinoma in the specimen
+Has one of the following histologically confirmed tumors: (NOTE: Evidence of diagnostic pathology of original biopsy confirmed by a CLIA/CAP certified laboratory must be available)
+Has one of the following histologically confirmed tumors:
+All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate; all patients must have metastatic disease as evidenced by soft tissue and/or bony metastases prior to initiation of androgen deprivation therapy
+Histologically confirmed, castrate-resistant adenocarcinoma of the prostate
+Histologically confirmed, previously untreated (treatment-naive) RCC
+Participants with Histologically or cytologically confirmed Stage III non-small cell lung cancer (NSCLC).
+Histologically confirmed recurrent or metastatic colorectal cancer
+Histologically or cytologically confirmed prostate adenocarcinoma
+Histologically documented adenocarcinoma (including the histologic variants of adenocarcinoma) of the colon or rectum
+Histologically confirmed unilateral primary invasive adenocarcinoma of the breast
+Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
+Histologically or cytologically confirmed diagnosis of relapsed or refractory advanced or metastatic malignancies:
+Part 2: histologically confirmed disease in specific tumor types
+Histologically or cytologically confirmed diagnosis of malignancy with demonstrated progression of a solid tumor (non-lymphoma) with no alternative standard-of-care therapeutic option (certain exceptions may apply).
+Histologically or cytologically confirmed transitional cell carcinoma of the genitourinary tract
+Histologically confirmed breast adenocarcinoma that is unresectable loco regional, or metastatic
+Must have histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.
+Histologically or cytologically confirmed carcinoma of the breast
+For the phase I portion, patients must have histologically and/or cytologically confirmed malignant solid tumor that is refractory to standard therapies
+Have histologically or cytologically confirmed melanoma
+Patients with a histologically or cytologically confirmed diagnosis of breast cancer; patients must have metastatic HER2 positive (+) disease
+Subject has a definitive histologically or cytologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas. Subjects with islet cell neoplasms are excluded.
+Subject has definitive histologically or cytologically confirmed Stage IIIB or IV NSCLC.
+Subject has a definitive histologically or cytologically confirmed diagnosis of HER2(-) metastatic breast cancer.
+Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features;
+Histologically- or cytologically-confirmed malignancy that is metastatic or unresectable and for which standard measures do not exist or are no longer effective (DEP) or a histologically confirmed diagnosis of PTCL based on pathology review at the local institution, using the most recent edition of the WHO Classification, relapsed or refractory disease after at least one prior systemic anticancer regimen (EXP in PTCL)
+Histologically and/or cytologically confirmed and radiographically measurable KRAS and NRAS wild-type adenocarcinoma of the colon or rectum that is metastatic and/or unresectable; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan and bevacizumab or have contraindication to such treatment
+Histologically confirmed solid tumor malignancy with greater than 5 sites of metastatic disease detected on cross-sectional imaging
+Patients with histologically confirmed intrahepatic, perihilar or extra-hepatic CCA.
+Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma
+Histologically confirmed unilateral or bilateral primary invasive carcinoma of the breast.
+Subjects with histologically or cytologically confirmed NSCLC:
+Have histologically confirmed microsatellite stable (MSS) CRC.
+Histologically or cytologically confirmed melanoma.
+Based on RECIST v1.1 criteria on current nivolumab treatment (prior to initiation of this study), has a best response of confirmed stable disease (SD) or confirmed progressive disease (PD). Confirmed SD or confirmed PD refers to a response that is confirmed by a 2nd scan which is at least 4 weeks apart from the previous scan.
+Subject must have histologically or cytologically confirmed solid tumor;
+Subjects must have histologically or cytologically confirmed advanced solid tumor for recurrent or metastatic disease.
+Has a histologically-confirmed or cytologically confirmed diagnosis of stage IV nonsquamous NSCLC.
+Histologically-confirmed disease
+Patients must have histologically or cytologically proven pancreatic adenocarcinoma; histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligible
+Has histologically confirmed non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.
+Histologically confirmed adenocarcinoma of the rectum
+Diagnosis - Dose Expansion Phase: Histologically or cytologically confirmed advanced RCC with a component of clear cell subtype
+Histologically confirmed, locally confined adenocarcinoma of the prostate
+Histologically-confirmed gastric or GEJ adenocarcinoma (Siewert type II/III classification) Or
+Histologically-confirmed inoperable superior, medial, or distal third esophageal adenocarcinoma (Siewert type I classification may be included, provided there is no mixed histology)
+Participant must have cytologically or histologically confirmed Non-small Cell Lung Cancer (NSCLC).
+Patients must have histologically or cytologically documented pancreatic adenocarcinoma; patients with pancreatic neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible
+Has histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features.
+Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
+Histologically or cytologically proven adenocarcinoma of the colon or rectum
+Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
+Histologically proven MCC
+Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, or small cell features;
+Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma
+Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum
+Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum
+Histologically or cytologically confirmed metastatic breast cancer
+Specific eligibility criteria for Part 2 CRPC expansion cohort: Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuously medically castrated (for >=8 weeks prior to pre-screening).
+Histologically or cytologically confirmed extensive-stage small-cell lung cancer (SCLC).
+Histologically confirmed (either previously or newly biopsied) metastatic unresectable pancreatic adenocarcinoma, including with intraductal papillary mucinous neoplasm.
+Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system)
+Histologically documented adenocarcinoma of the prostate
+Histologically or cytologically confirmed diagnosis of pancreatic cancer.
+Has histologically confirmed biliary tract adenocarcinoma with documented progression after 1-2 prior lines of systemic therapy
+Histologically confirmed diagnosis of DLBCL
+Histologically or cytologically confirmed advanced fibrolamellar carcinoma (FLC).
+Histologically proven diagnosis of pancreatic ductal adenocarcinoma (PDAC)
+The subject has histologically or cytologically proven adenocarcinoma of the breast that is HER2+
+Subjects must have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma; subjects with islet cell neoplasms are excluded
+Histologically proven colorectal adenocarcinoma
+Histologically or cytologically documented diagnosis of NSCLC
+Patients must have histologically or cytologically confirmed diagnosis (from primary lesion and/or lymph nodes) of Squamous Cell Cancer of the oropharynx, hypopharynx or larynx (For patients with oropharynx primary, the tumor must be negative for p16 by immunohistochemistry).
+Histologically or cytologically-confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra.
+Inclusion Criteria:\n\n        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\n        visit www.BMSStudyConnect.com\n\n          -  Patients with metastatic or advanced solid tumors\n\n          -  Women with histologically or cytologically confirmed triple negative breast carcinoma\n\n          -  Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n\n          -  Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer\n             (NSCLC)\n\n        Exclusion Criteria:\n\n          -  Active brain metastases or leptomeningeal metastases.\n\n          -  Any serious or uncontrolled medical disorder\n\n          -  Prior malignancy active within the previous 3 years\n\n        Other protocol defined inclusion/exclusion criteria could apply
+Histologically confirmed diagnosis of R/R AITL (eligibility needs to be confirmed by central pathological review).
+Histologically or cytologically confirmed Stage IIIB-IVB NSCLC
+Pathologically confirmed MCL.
+Have a histologically or cytologically confirmed diagnosis of non-resectable, recurrent, or metastatic biliary tract adenocarcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or Ampulla of Vater) .
+Histologically confirmed diagnosis of FL or MCL according to WHO 2008
+Histologically confirmed unresectable advanced or recurrent esophageal cancer
+A histologically or cytologically confirmed cancer that is metastatic, unresectable, or recurrent and for which treatment with ipilimumab, or nivolumab, or pembrolizumab is a reasonable therapeutic option in the opinion of the investigator.
+Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma.
+Have histologically or cytologically confirmed squamous NSCLC.
+Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC
+Histologically or cytologically confirmed urothelial carcinoma of the bladder or mixed histology bladder cancer
+Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, gastric adenocarcinoma, cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with a gastrointestinal primary suspected), or other primary gastrointestinal malignancy for which the treating physician feels that FOLFIRABRAX is a reasonable therapeutic option
+Subjects must have histologically or cytologically confirmed untreated metastatic pancreatic adenocarcinoma; subjects with islet cell neoplasms are excluded; subjects with mixed histology will be excluded
+Confirmed diagnosis of HER2 positive disease
+Histologically or cytologically confirmed diagnosis of unresectable or metastatic malignant melanoma, including cutaneous, ocular, mucosal and unknown primary tumour.
+Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).
+Histologically confirmed, localized adenocarcinoma of the prostate
+Histologically or cytologically confirmed non-small cell lung cancer; patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study; neuroendocrine carcinomas are not eligible; carcinomas with neuroendocrine differentiation are eligible
+The patient has histologically, or cytologically, confirmed adenocarcinoma of the prostate.
+Histologically or cytologically confirmed metastatic breast cancer relapsed or refractory to approved standard available treatment
+Histologically confirmed adenocarcinoma of the pancreas that has been documented to be resectable by standardized radiographic criteria by a pancreatic surgeon
+Histologically confirmed cancer (one of the following):\r\n* Metastatic pancreatic adenocarcinoma
+Malignant pleural mesothelioma (histologically confirmed epithelial)
+Histologically and/or cytologically confirmed and radiographically evaluable refractory metastatic colorectal adenocarcinoma for which regorafenib would be considered a therapeutic option
+Histologically- or cytologically-confirmed diagnosis of advanced/unresectable or metastatic MEL or RCC (Part 1A only) with predominantly clear cell elements
+Participants must have histologically confirmed B-cell NHL
+Histologically or cytologically confirmed carcinoma of the breast
+Has histologically or cytologically confirmed advanced, measurable or non-measurable metastatic solid tumors for which the patients have no available therapy to convey clinical benefit Expansion Phase only: The target population should include at least
+Histologically confirmed diagnosis of melanoma
+Patients must have histologically or cytologically confirmed evidence of pancreatic carcinoma
+Histologically or cytologically confirmed diagnosis of HCC
+Confirmed diagnosis of HER2 positive disease
+Histologically confirmed diagnosis of malignant melanoma.
+Histologically confirmed melanoma of cutaneous origin
+Patients must have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (or any mixed pathology if adenocarcinoma is predominant)
+Non-metastatic operable primary invasive HER2-positive carcinoma of the breast that is histologically confirmed, and adequately excised
+Confirmed HER2 positive status
+Histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease.
+Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis
+Have histologically or cytologically confirmed SCLC (undifferentiated small-cell carcinoma arising in or consistent with lung cancer origin).
+Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.
+Histologically and/or cytologically confirmed and radiographically measurable adenocarcinoma of the colon or rectum that is metastatic and/or unresectable; subjects must have been treated with a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, and an anti-VEGF monoclonal antibody (bevacizumab, ramucirumab, or ziv-aflibercept), or have contraindication to such treatment
+Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate
+Females 18 years old and greater with histologically or cytologically confirmed diagnosis of advanced or metastatic adenocarcinoma of the breast.
+Histologically documented diagnosis of DLBCL.
+Histologically or cytologically proven metastatic breast cancer (metastases can be proven with imaging results in certain circumstances provided that the initial tumor was demonstrated histologically)
+Histologically or cytologically confirmed diagnosis of metastatic uveal melanoma (mUM)
+Histologically or cytologically confirmed T 3/4 or N+ (> 1 cm in size or fludeoxyglucose F-18 [FDG] avid) gastric or gastroesophageal (GE) junction cancer; diagnosis must be confirmed a Dana-Farber (DF)/Harvard Cancer Center (HCC) institution pathology department prior to registration
+Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) (Stage IIIb or greater)
+Histologically confirmed colorectal cancer that is either clinically or histologically proven to be metastatic and has progressed on regimens containing a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, bevacizumab and an anti-EGFR antibody (if tumor is RAS wild-type), or where the treatment was not tolerated or contraindicated
+Patients must have a histologically confirmed diagnosis of Ph+ ALL
+Histologically or cytologically confirmed locally advanced or metastatic pancreatic ductal adenocarcinoma. Patients with acinar cell carcinoma may also be included.
+Histologically or cytologically confirmed metastatic solid tumor, including but not limited to pancreatic adenocarcinoma, breast cancer, melanoma, renal cell carcinoma (RCC), colorectal adenocarcinoma, non-small cell lung cancer, and others approved by the principal investigator
+Histologically or cytologically confirmed metastatic and/or unresectable progressive, well differentiated carcinoid or pancreatic neuroendocrine tumor (NET) carcinoids
+Histologically or cytologically confirmed metastatic PDAC, no more than 1 prior chemotherapy regimen or treatment-naïve patients
+Histologically or cytologically confirmed primary disease histology of solid ovarian, fallopian tube, or primary peritoneal tumor categorization
+Postmenopausal women with histologically or cytologically confirmed invasive, ER+/HER- (defined by local guidelines) metastatic or inoperable, locally advance breast cancer
+Histologically or cytologically confirmed locally advanced or metastatic colon or rectal adenocarcinoma
+Patients must have histologically confirmed diagnosis of unresectable malignant pleural mesothelioma
+Histologically or cytologically confirmed pancreatic adenocarcinoma
+Participant has histologically or cytologically confirmed squamous or non-squamous non-small cell lung cancer (NSCLC).
+Patients must have histologically confirmed, untreated non-small cell lung cancer that are considered non-metastatic, unresectable for which chemoradiation is the definitive therapy
+Histologically or cytologically confirmed advanced RCC with clear cell component
+Histologically confirmed pancreatic adenocarcinoma
+Histologically or cytologically confirmed small cell lung cancer (SCLC)
+Histologically proven adenocarcinoma of the prostate
+Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma
+Histologically confirmed recurrent or metastatic NSCLC (adenocarcinoma, large cell, squamous cell, or not otherwise specified) that has either progressed during or after platinum-based chemotherapy
+Histologically- or cytologically- confirmed CRC
+Participants must have unresectable or metastatic histologically confirmed intrahepatic cholangiocarcinoma
+Histologically or cytologically confirmed low or intermediate grade, unresectable well differentiated foregut neuroendocrine tumors (thymic, bronchopulmonary, gastric, duodenal and pancreatic); patients with multiple neuroendocrine tumors associated with MEN1 syndrome will be eligible
+Patients must have histologically or cytologically confirmed gastrointestinal (GI) malignancies or ovarian cancer prior to entering this study
+Histologically or cytologically confirmed pleural or peritoneal malignant mesothelioma, epithelial, sarcomatoid, or biphasic subtypes
+Patient must have histologically or cytologically confirmed intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer or may undergo a repeat biopsy for histologic confirmation if pre-existing biopsy is not sufficient for diagnosis
+Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, or signet cell or small cell features;
+Patients must have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (or any mixed pathology if adenocarcinoma is predominant)
+Subject has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive breast cancer by local laboratory (based on most recently analyzed biopsy).
+Histologically- or cytologically-confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma
+Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:
+Histologically confirmed diagnosis of FL grade 3b.
+Histologically or cytologically confirmed advanced pancreatic ductal adenocarcinoma that is unresectable or metastatic
+Histologically or cytologically proven metastatic or inoperable pancreatic adenocarcinoma
+Patients must have histologically or cytologically confirmed carcinoma of the pancreas; most cases will be adenocarcinoma; cases with “undifferentiated” or “poorly differentiated” carcinoma will also be eligible
+Histologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastases
+Histologically confirmed glioblastoma
+Patients must have histologically or cytologically confirmed previously treated metastatic squamous cell carcinoma of the anal canal
+Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma; patients without histologically confirmed adenocarcinoma may be eligible if both the treating physician and the study principal investigator (PI) agree that the patient’s history is unambiguously indicative of advanced adenocarcinoma
+Pathologically confirmed adenocarcinoma of the lung.
+Histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas that is considered unresectable or borderline resectable based on institutional standardized criteria of unresectability or medical inoperability; patients with and without regional adenopathy are eligible
+Metastatic histologically or cytologically confirmed uveal melanoma with pathologic confirmation at a participating center that is judged to be progressive in the opinion of the treating physician; for the dose escalation portion of the trial only, patients with non-uveal melanoma harboring a GNAQ or GNA11 mutation will also be eligible
+Subject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC and are current or former smokers.
+Histologically- or cytologically-confirmed recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies
+Have histologically- or cytologically-proven adenocarcinoma of the pancreas; patients with mixed histology will be excluded
+Histologically or cytologically confirmed invasive breast cancer with distant metastasis
+Histologically confirmed recurrent or metastatic SCCHN
+Histologically documented adenocarcinoma of the prostate
+Histologically or cytologically proven diagnosis of non-small cell lung cancer
+Subjects with histologically or cytologically documented NSCLC.
+Patients with histologically or cytologically confirmed solid malignancy are eligible for treatment as long as insurance approval for docetaxel is obtained
+Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants)
+Histologically or cytologically confirmed advanced RCC with predominantly clear-cell subtype with primary tumor resected
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed carcinoma of the prostate
+Subject must have cytologically or histologically confirmed squamous NSCLC.
+Histologically or cytologically confirmed diagnosis of pancreatic carcinoma (dose escalation and MTD expansion components).
+Histologically confirmed papillary serous adenocarcinoma or endometrioid type of endometrial carcinoma (histological documentation of recurrence is not required);
+Histologically confirmed adenocarcinoma of the prostate
+Histologically proven adenocarcinoma of the prostate
+Histologically confirmed adenocarcinoma of the prostate
+Participants must have histologically or cytologically confirmed MCC that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate without > 50% neuroendocrine differentiation or small cell histology
+A histologically confirmed solid tumor of the gastrointestinal tract including
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+COHORT A: The subject must have histologically confirmed adenocarcinoma of the prostate with tissue confirmation at selected study site
+Histologically or cytologically confirmed GIST by the Laboratory of Pathology, National Cancer Institute (NCI)
+Histologically or cytologically confirmed non-muscle invasive bladder cancer [Ta, T1 or Tis (CIS)] that has been removed by transurethral resection
+Patients with unresectable or metastatic histologically confirmed sporadic or NF1 associated high grade MPNST
+Histologically confirmed malignant pleural mesothelioma that is not metastatic or unresectable
+Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
+Have pathologically confirmed colon or rectal adenocarcinoma
+Subject has histologically confirmed metastatic adenocarcinoma of the prostate.
+Histologically or cytologically proven diagnosis of prostate cancer.
+Non-metastatic histologically confirmed primary invasive breast carcinoma that was operable
+Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate
+Participants must have histologically or cytologically confirmed cervical cancer which is now recurrent or metastatic and is refractory to curative therapy or established treatments; histologic or cytologic confirmation of the original primary tumor is required; all histologic types of cervical origin are permitted
+Patients must have histologically confirmed adenocarcinoma of the prostate gland
+Pathologically or cytologically confirmed esophagogastric cancer
+Histologically confirmed squamous cell carcinoma of the cervix (any grade) or histologically confirmed grade 1 or 2 adenocarcinoma of cervix
+Histologically or cytopathologically confirmed adenocarcinoma of the pancreas
+Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma (MPM)
+Diagnosis of histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum.
+Patients must have a histologically confirmed diagnosis of epithelioid, sarcomatoid, or mixed-type malignant pleural or peritoneal mesothelioma that is not amenable to surgery
+Histologically or cytologically confirmed diagnosis
+Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate without >= 50% neuroendocrine differentiation or small cell histology
+Histologically or cytologically proven SCLC that has relapsed or been refractory after at least one line of chemotherapy
+Histologically confirmed adenocarcinoma of the prostate
+Eligibility for the expansion cohort: histologically or cytologically confirmed metastatic or unresectable pancreatic adenocarcinoma for which curative treatment does not exist
+Eligibility for the expansion cohort: Histologically or cytologically confirmed colon or rectal adenocarcinoma for which curative treatment does not exist; patients must have documented progression or intolerance to at least one prior regimen containing 5-fluorouracil or capecitabine and oxaliplatin
+Patients must have a histologically or cytologically confirmed non-central nervous system (CNS) primary solid malignancy at the time of initial diagnosis; NOTE: brain lesions are not required to have pathologic confirmation; in addition, a copy of the pathology report for the primary tumor is sufficient for registration purposes
+Subjects must have a cytological or histological confirmed diagnosis of adenocarcinoma of the lung.
+Histologically-confirmed non-germinal center B-cell subtype DLBCL
+A histological diagnosis of adenocarcinoma of the pancreas confirmed by pathology.
+Histologically and cytologically confirmed metastatic pancreatic adenocarcinoma
+Participants must have histologically or cytologically confirmed advanced (stage IV or recurrent) non-small cell lung cancer
+Patients must have histologically or cytologically confirmed advanced or metastatic cancer for which capecitabine treatment is considered a standard treatment option
+Patient has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as assessed by the FDA approved Abbott FISH Test.
+Histologically or cytologically documented NSCLC
+Participants must have histologically confirmed prostate cancer.
+Histologically proven adenocarcinoma of the prostate
+Patients must have histologically confirmed malignancy that is metastatic or unresectable
+A histologically or cytologically confirmed colorectal cancer that is metastatic, unresectable, or recurrent.
+Histologically confirmed metastatic adenocarcinoma of the stomach or GEJ
+Histologically or cytologically confirmed metastatic or recurrent NSCLC; primary or metastatic site may be used for histology
+Histologically confirmed invasive breast carcinoma
+Histologically or cytologically confirmed, locally advanced, inoperable, or metastatic solid tumors. Subjects eligible for enrollment in the Expanded Cohort must have documented and/or confirmed FGFR genetic alterations, including iCCA with FGFR2 gene fusion.
+Histologically or cytologically proven prostate carcinoma
+Histologically confirmed diagnosis of mycosis fungoides (MF) or Sezary Syndrome (SS)
+Histologically confirmed AL or LCDD (from any time prior to screening)
+Histologically confirmed V600E or V600K BRAF mutant melanoma
+Histologically or cytologically confirmed adenocarcinoma of the prostate
+Diagnosis of non-small cell lung cancer (NSCLC), histologically or cytologically confirmed
+In the dose-expansion phase: histologically- or cytologically- confirmed advanced solid tumor where if an approved first-line therapy is available, subjects must have failed, be intolerant to, be ineligible for, or have refused
+Histologically or cytologically confirmed adenocarcinoma of the prostate at either MSKCC or at the participating site
+histologically-confirmed diagnosis according to REAL/WHO classification, of the following B-cell lymphomas :
+Histologically-  or cytologically-confirmed, treatment naive (or status post treatment regimens of tyrosine kinase inhibitor and/or immunotherapy) stage IV non-squamous, NSCLC
+Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following:
+Histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with a gastrointestinal primary suspected), or other primary gastrointestinal malignancy for which the treating physician feels that mFOLFIRINOX is a reasonable therapeutic option
+Histologically confirmed CD30+ disease by central laboratory assessment and pathology review
+Phase Ia: Patients must have histologically or cytologically documented metastatic solid tumor malignancies
+Phase Ib: Patients must have histologically or cytologically confirmed locally advanced renal cell carcinoma
+Subjects must have a histologically or cytologically confirmed metastatic or unresectable\r\n* Solid tumor (for phase I dose escalation portion), OR\r\n* virally mediated tumors (such as with HPV+ nasopharyngeal cancer, HPV+ cervical cancer) and liposarcoma (for expansion cohort)
+Patients must have a histologically confirmed diagnosis of endometrial cancer and no clinical evidence of extra-uterine disease on preoperative evaluation
+The patient has histologically or cytologically confirmed pancreatic adenocarcinoma.
+Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic.
+Histologically confirmed diagnosis of melanoma
+Participants must have histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma
+Patients must have histologically or cytologically confirmed adenocarcinoma of the pancreas; patients who have not undergone biopsy but have highly suspected adenocarcinoma of the pancreas with borderline resectable features on imaging study may also be eligible for study and undergo the pretreatment biopsy as per protocol; the biopsy must confirm adenocarcinoma of the pancreas to continue on study; biopsy is required within 14 days of starting therapy
+Subjects must have histologically-confirmed chordoma
+Participants must have histologically or cytologically confirmed carcinoma; central pathology review is not required; however, pathology will be reviewed at Brigham and Women's Hospital (BWH)/Dana-Farber Cancer Institute (DFCI)
+Patients’ biopsies must be histologically confirmed CD30 positive within 36 months of enrollment
+I 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.
+Histologically confirmed, unresectable, metastatic diffuse gastric cancer including carcinoma of the gastro-esophageal junction
+Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
+Patients must have histologically confirmed adenocarcinoma of the small bowel or ampulla of Vater that is either unresectable or metastatic
+histologically or cytologically proven diagnosis of malignancy other than NSCLC
+History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease; confirmation of diagnosis must be performed by the enrolling institution
+Patients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.
+Histologically confirmed adenocarcinoma of the prostate with metastatic disease.
+Histologically confirmed Stage 4 or recurrent non-small cell lung cancer
+Histologically-confirmed HL
+Histologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after prior chemotherapy (only one prior systemic therapy allowed)
+Histologically confirmed diagnosis of prostate cancer
+Patients must have histologically or cytologically confirmed metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma; GEJ adenocarcinoma may be classified according to Siewert’s classification type I, II, or III
+Patients must have histologically or cytologically confirmed urothelial tract carcinoma
+Histologically or cytologically proven diagnosis of metastatic ductal adenocarcinoma of the pancreas.
+Histologically or cytologically confirmed NSCLC
+Histologically or cytologically confirmed urothelial carcinoma.
+Histologically confirmed adenocarcinoma of the prostate.
+Dose escalation phase: patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; OR safety dose expansion phase: patients must have histologically or cytologically confirmed relapsed or refractory small cell lung cancer
+Patients must have histologically or cytologically confirmed invasive cancer of the breast
+Histologically or cytologically confirmed adenocarcinoma of the pancreas.
+Histologically or cytologically confirmed stage IIIB or IV NSCLC with non-squamous histology
+Histologically or cytologically confirmed diagnosis of small cell lung carcinoma. Subjects must have measurable disease per RECIST 1.1 (for Part 2 only).
+Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:
+Histologically or cytologically confirmed diagnosis of metastatic colorectal cancer with a product related mutation in Ras (G12V, G12C, G12D, G12R, Q61L, Q61R, Q61H)
+Histologically or cytologically confirmed squamous or non-squamous NSCLC
+Patients must have a histologically or cytologically confirmed metastatic solid tumor malignancy for the phase I component; the phase II component will require patients to have histologically or cytologically confirmed non-small cell lung carcinoma regardless of histology
+Must have histologically or cytologically confirmed non-squamous NSCLC.
+Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
+Histologically or cytologically confirmed diagnosis of an advanced nonhematological malignancy (Part A) or advanced pancreatic adenocarcinoma (Part B) that is not surgically resectable
+Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas.
+Histologically confirmed colon or rectal cancer with metastatic disease
+Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II, III)
+Histological diagnosis of pancreatic adenocarcinoma confirmed pathologically, OR
+Histologically confirmed diagnosis of classical HL
+Histologically confirmed MCL
+Histologically or cytologically confirmed diagnosis of CRC
+Histologically or cytologically confirmed adenocarcinoma of the prostate without signet ring cell features.
+Histologically proven small cell lung cancer with progressive parenchymal brain involvement confirmed by imaging
+A histological diagnosis of adenocarcinoma of the pancreas confirmed by pathology.
+Has a histologically and/or cytologically confirmed diagnosis of NSCLC (squamous or nonsquamous).
+Patients must have histologically or cytologically confirmed localized (T1N1-3M0 or T2-4NanyM0, stage IB-III) Siewert type 1 or type 2 esophageal adenocarcinoma that is amenable to surgical resection as determined by a thoracic surgeon and for which all disease (primary tumor and involved lymph nodes) can be treated with radiation, as determined by a radiation oncologist
+Histologically confirmed diagnosis of B-lineage ALL. Verification of CD22 expression is not required
+Histologically confirmed metastatic and/or advanced mesothelin-positive PDA as determined by central pathology lab review
+Patients must have histologically confirmed gastric, gastro-esophageal junction or distal esophageal adenocarcinoma (predominant histology) that is recurrent, metastatic or unresectable
+Subjects must have histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the intrathoracic esophagus, gastrointestinal junction or stomach
+Histologically or cytologically confirmed diagnosis of NSCLC that is Stage IIIb, IV, or recurrent.
+Must have histologically confirmed DLBCL that is relapsed or refractory to previous therapy.
+Histologically confirmed primary invasive adenocarcinoma of the breast
+Histologically confirmed DLBCL(Cohort C)
+Histologically confirmed metastatic or advanced inoperable adenocarcinoma of the pancreas with immunohistochemistry (IHC) evidence of guanylyl cyclase C (GCC) expression indicated by an H-score of 10 or greater.
+Histologically confirmed metastatic or advanced inoperable adenocarcinoma of the stomach or gastroesophageal junction with immunohistochemistry (IHC) evidence of guanylyl cyclase C (GCC) expression indicated by an H-score of 10 or greater.
+Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma (IHC) without distant extrahepatic metastasis within 90 days of registration; patients with an adenocarcinoma suggestive of a pancreaticobiliary primary with radiographic findings consistent with an intrahepatic cholangio-carcinoma are eligible
+Histologically or cytologically confirmed (extensive-stage disease) ED SCLC (small cell lung cancer)
+Stage IV, histologically or cytologically confirmed NSCLC; confirmation may be obtained with the first protocol-specified tumor biopsy
+Must have cytologically or histologically confirmed NSCLC with either:
+Patients must have histologically or cytologically confirmed cancer
+Histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast
+Histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic.
+Histologically or cytologically confirmed adenocarcinoma of the pancreas.
+Histologically confirmed CD20 positive primary B-cell CNS lymphoma (PCNSL) confirmed by one of the following:
+Patients must have a histologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic to the liver and unresectable and for which standard curative measures do not exist or are no longer effective
+Histological diagnosis of pancreatic adenocarcinoma confirmed pathologically, OR
+Histologically proven GBM
+Documented histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed adenocarcinoma of the pancreas
+Patients in Parts 2 and 3 must have histologically confirmed diagnosis of CD30-positive DLBCL
+Patient has histologically/cytologically-confirmed HNSCC.
+Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC
+Patient has histologically or cytologically confirmed localized adenocarcinoma of the pancreas including tumors in the pancreatic head, uncinate process, neck, body and tail that are potentially resectable by pancreatico-duodenectomy (Kausch-Whipple procedure); patients with islet cell or other neuroendocrine neoplasms are excluded
+Histologically confirmed colorectal cancer with at least one measurable metastatic lesion by RECIST v 1.1, that is considered unresectable at baseline
+Histologically confirmed diagnosis of osteosarcoma with lung metastasis, who have progressed on the prior line of therapy, or relapsed
+Histologically confirmed colorectal cancer
+Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective OR\r\n* Histologically or cytologically confirmed solid tumor for which single agent capecitabine is an appropriate treatment option
+Patient has histologically or cytologically confirmed borderline resectable adenocarcinoma of the pancreas; patients with islet cell or other neuroendocrine neoplasms are excluded
+Confirmed pancreatic ductal adenocarcinoma
+Patients with histologically/cytologically-confirmed HNSCC
+Histologically confirmed glioblastoma multiforme or gliosarcoma
+Histologically or cytologically confirmed invasive breast carcinoma at local institution
+Histologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction with metastatic disease documented to involve at least liver or lung or both
+LUNG ADENOCARCINOMA COHORT (COHORT 3 ONLY): Subjects must have histologically confirmed advanced (stage IIIB/IV) lung adenocarcinoma; the diagnosis will be confirmed by the Laboratory of Pathology/CCR/NCI
+Histologically or cytologically confirmed prostate cancer
+Histologically confirmed non-squamous histologies are not allowed; an exception is made for WHO type I-III nasopharynx histologies
+Histologically or cytopathologically confirmed adenocarcinoma of the pancreas
+Histologically or cytologically confirmed diagnosis of inoperable colorectal adenocarcinoma, pancreatic, hepatocellular, cholangiocarcinoma, small bowel, gastric or esophageal adenocarcinoma that carries an activated ALK or ROS1 pathway
+Have a histologically or cytologically confirmed diagnosis of stage IV NSCLC.
+Histologically confirmed squamous cell lung cancer
+Patients must have histologically or cytologically confirmed stage IV or recurrent squamous cell lung cancer that harbors any of the NFE2L2 mutations; any KEAP1 mutation will be eligible
+Histologically or cytologically confirmed adenocarcinoma of the prostate.
+Histologically confirmed:
+Histologically or cytologically confirmed adenocarcinoma consistent clinically with androgen independent prostate cancer
+Histologically confirmed uterine leiomyosarcoma with disease limited to the uterus (determined by surgical staging or radiologic imaging).
+Histologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer
+Documented histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed disease;
+For the expansion cohort: women with histologically or cytologically confirmed TNBC (triple negative breast cancer)
+Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer
+Histologically confirmed adenocarcinoma of the prostate
+Treatment Group A (TGA): Part 1 and Part 2: Any advanced solid tumor or lymphoma; Part 3: Histologically confirmed disease in specific solid tumors and lymphomas
+Histologically or cytologically confirmed Stage IV non-squamous NSCLC
+Histologically or cytologically confirmed solid tumor.
+Patient with histologically/cytologically confirmed Primary Central Nervous System Lymphoma (PCNSL)
+Part A Subjects with histologically or cytologically confirmed malignant advanced solid tumors, who have progressed on at least 1 prior chemotherapy, and for whom either
+Histologically or cytologically confirmed Stage IV squamous NSCLC
+Subjects must have histologically confirmed local adenocarcinoma of the prostate and have elected to proceed with radical prostatectomy as the primary curative therapy
+Histologically documented FL (Grade 1, 2 and 3A)
+Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:
+Patients must have a histologically confirmed, unresectable pancreatic adenocarcinoma
+Histologically confirmed diagnosis of B-cell iNHL, with histological subtype limited to the following:
+Histologically or cytologically proven adenocarcinoma of the breast
+Participants must have histologically or cytologically confirmed diagnosis of SCLC
+Histologically or cytologically proven pancreatic carcinoma or adenocarcinoma; histologies other than carcinoma/adenocarcinoma will not be eligible
+Documented histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed primary, untreated SCCHN including variants. Patients must be candidates for surgical resection. Primary tumors of oral cavity, oropharynx, hypopharnyx or larynx are included.
+Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary, follicular, or poorly differentiated subtypes and their respective variants).
+Histologically or cytologically proven squamous non-small cell lung cancer (NSCLC) where treatment with weekly paclitaxel is an appropriate treatment option.
+Diagnosis of histologically or cytologically confirmed prostate adenocarcinoma.
+Histologically or cytologically confirmed Stage IIIB or IV advanced or metastatic NSCLC with measurable neoplastic disease. Sputum cytology alone is not considered an acceptable method of diagnosis;
+Patients with relapsed small cell lung cancer – diagnosis must be histologically confirmed
+Histologically confirmed GBM
+Subjects with a histologically or cytologically confirmed acute leukemia who are refractory to or have exhausted all available therapies
+Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum
+Histologically documented leiomyosarcoma
+Histologically or cytologically confirmed Stage IIIB or IV Non-Small Cell Lung Cancer.
+Histologically or cytologically confirmed refractory colorectal cancer
+Diagnosis of NSCLC, histologically or cytologically confirmed
+Have histologically confirmed breast or ovarian carcinoma
+Histologically or cytologically proven adenocarcinoma of the pancreas; if the patient has mixed tumor with predominant adenocarcinoma pathology, they can be enrolled
+Histologically confirmed adenocarcinoma of the prostate
+Histologically or cytologically confirmed colorectal adenocarcinoma
+Histologically or cytologically confirmed mCRC not amenable to potentially curative resection with at least one measurable metastatic lesion, as defined by RECIST v1.1
+Histologically-documented prostatic adenocarcinoma in >= 2 cores
+Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC
+Patients must have histologically or cytologically confirmed low or intermediate grade pancreatic NET; patients with neuroendocrine tumors associated with multiple endocrine neoplasia type 1 (MEN1) syndrome will be eligible
+Histologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.
+Have a histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma, or primitive hepatocarcinoma with radiological diagnosis
+Histologically or cytologically confirmed diagnosis of a solid tumor.
+Histologically or cytologically confirmed unresectable NSCLC
+Dose escalation phase: Subjects with histologically or cytologically confirmed advanced malignancies (solid tumors and malignant lymphomas) who were refractory to or had exhausted all available therapies. Subjects had to have evaluable or measurable disease (as per RECIST 1.1 or Cheson 2007 criteria).
+For paclitaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease
+Histologically or cytologically confirmed solid tumor (Part 1) or pancreatic adenocarcinoma (Part 2)
+Histologically or cytologically proven adenocarcinoma of the prostate
+Histologically confirmed diagnosis of PTCL
+Histologically or cytologically confirmed invasive carcinoma of the breast
+Histologically or cytologically documented breast cancer
+Histologically or cytologically confirmed adenocarcinoma of the breast.
+Histologically confirmed endometrial cancer
+Subject must have histologically or cytologically confirmed gastric, or gastroesophageal adenocarcinoma, or distal esophageal adenocarcinoma.
+Histologically proven adenocarcinoma of the prostate
+Patient must have histologically or cytologically confirmed colorectal adenocarcinoma or small bowel adenocarcinoma
+Patient must have histologically or cytologically confirmed refractory colorectal cancer (CRC)
+Histologically confirmed adenocarcinoma of the prostate
+Dose expansion cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or papillary histology
+Cytopathologically or histologically confirmed diagnosis of MM
+Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
+DOSE ESCALATION COHORT: subjects must have histologically or cytologically confirmed sarcoma that is metastatic or unresectable
+DOSE EXPANSION COHORT: subjects must have histologically or cytologically confirmed GIST that is metastatic or unresectable
+Histologically or cytologically confirmed diagnosis of a solid tumor for which no further effective standard treatment is available. Patients with lymphomas may be enrolled.
+Histologically or cytologically confirmed melanoma
+Histologically or cytologically confirmed hepatocellular carcinoma that is metastatic, unresectable, or recurrent.
+Histologically confirmed relapsed or refractory FL (Grades 1, 2, or 3a) or relapsed or refractory DLBCL
+Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuous medical castration (for >=8 weeks prior to Screening)
+Histologically or cytologically confirmed locally residual or recurrent cancer of the rectum or anus
+Histologically confirmed angiosarcoma
+Histologically confirmed non-small cell lung cancer
+Histologically-confirmed metastatic adenocarcinoma of the breast (confirmation will be done at Memorial Sloan Kettering Cancer Center [MSKCC])
+Histologically- or cytologically-confirmed MPeM; epithelial, sarcomatoid, biphasic, multi-cystic, or well-differentiated papillary subtypes are allowed
+Histologically or cytologically confirmed adenocarcinoma of the prostate;
+For Stage 2: Participants with histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC); mixed histology that is predominantly squamous is acceptable
+Histologically proven adenocarcinoma of the prostate
+Histologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumor
+Histologically or cytologically documented non-small cell lung cancer (NSCLC)
+Have histologically proven malignant adenocarcinoma of the pancreas; measurable disease is not required. (Subjects with mixed histology will be included if the predominant component is adenocarcinoma. Subjects must have metastatic disease.)
+Histologically or cytologically confirmed non-squamous NSCLC
+Histologically or cytologically confirmed R/M HNSCC of the oral cavity, oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapy
+Histologically confirmed diagnosis of conventional chondrosarcoma of any grade.
+Histologically or cytologically confirmed diagnosis of solid tumor in advanced stage which taxane-based therapy is a rational treatment option.
+Part F - Histologically- or cytologically-confirmed gastric carcinoma, including gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma (participants with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the GEJ). Participants must be ramucirumab naïve. Participants must be, in the opinion of the investigator, an appropriate candidate for experimental therapy. human epidermal growth factor receptor 2 (HER2)/neu status should be documented, if known.
+Patients must have histologically or cytologically confirmed metastatic uveal melanoma
+Patients aged ?18 years with a histologically or cytologically confirmed diagnosis of a solid tumor or lymphoma for which no further effective standard treatment is available
+The participant has histologically or cytologically confirmed, nonsquamous (adenocarcinoma/large cell or other) NSCLC.
+Histologically or cytologically confirmed invasive breast carcinoma
+Confirmed NSCLC
+Histologically/cytologically proven colorectal carcinoma
+histologically or cytologically proven diagnosis of non-small cell lung cancer
+Patients must have histologically confirmed solid tumor malignancy or lymphoma that is metastatic or unresectable and for which effective therapy does not exist or is no longer effective
+Histologically or cytologically confirmed breast carcinoma
+Histologically documented recurrent/metastatic adenocarcinoma of the breast with a recurrence on the chest wall (or its overlying skin):
+Histologically or cytologically confirmed HER2-positive invasive breast cancer, with Stage IV disease;
+Histologically or cytologically confirmed adenocarcinoma of the prostate;
+Histologically or cytologically confirmed salivary gland carcinoma.
+Histologically confirmed unilateral primary invasive adenocarcinoma of the breast
+Have a histologically or cytologically-confirmed diagnosis of adenocarcinoma of the GEJ or stomach
+Histologically or cytologically confirmed metastatic stage IIIB/IV lung adenocarcinoma with known activating mutations in the EGFR TK domain (including exon 19 deletion and L858R)
+Phase Ib: Histologically or cytologically confirmed adenocarcinoma of the pancreas, colon or rectum which disease is advanced (defined as not surgically curable) or metastatic in whom combination treatment using fluorouracil, oxaliplatin and irinotecan is a rational option
+Histologically or cytologically confirmed diagnosis of mCRC
+Histologically confirmed diagnosis of myeloma
+Patients must have histologically confirmed diagnosis of recurrent, persistent or advanced (stage IVB) squamous, adenocarcinoma or adenosquamous cervical cancer
+Histologically or cytologically confirmed unresectable or metastatic esophagogastric adenocarcinoma
+Histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC
+Patients must have histologically or cytologically confirmed malignant melanoma and clinical evidence of metastatic disease to the brain; mucosal and ocular melanomas are included
+Histologically or cytologically confirmed diagnosis of solid malignancy
+Histologically or cytologically confirmed diagnosis of prostate cancer
+Have histologically or cytologically-confirmed malignant disease in an advanced incurable stage
+Histologically/cytologically proven primary thoracic or breast malignancy, lymphoma or lung metastases (which are not required to be biopsy-proven) treated with definitive intent
+Histologically confirmed cancer diagnosis
+Histologically-confirmed adenocarcinoma of the prostate
+Histologically confirmed diagnosis for which an allogeneic transplant is utilized
+Histologically or cytologically confirmed diagnosis of HNSCC associated with HPV by a p16 immunohistochemistry (IHC) assay or HPV-16 or HPV-18 positive by nucleic acid testing.
+Histologically or cytologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction (GEJ); pathology must be confirmed at Memorial Sloan Kettering Cancer Center
+Histologically and/or cytologically confirmed diagnosis of ER+/HER2- breast cancer
+Patients must have histologically or cytologically confirmed stage II-IV lung cancer and be planned for or within 2 weeks of initiation of initial non-surgical therapy
+Must have a histologically confirmed cancer diagnosis
+Adolescents and young adults (AYA) with histologically confirmed cancer who have completed primary treatment
+Histologically or cytologically confirmed, stage I-III breast cancer
+Histologically-documented localized (stage < T3) prostate adenocarcinoma
+Patients must have histologically confirmed T3-T4 and N0-N2, M0 adenocarcinoma of the rectum with the inferior margin within 16 cm from the anal verge
+Histologically confirmed breast cancer and no evidence of metastatic disease with a recommendation to begin chemotherapy within 4 weeks
+Histologically confirmed carcinoma of the breast
+History of histologically confirmed prostate cancer
+Adult men of all races and body size with histologically confirmed localized PCa on AS
+Have histologically confirmed cancer
+CANCER PATIENT GROUP: Histologically confirmed non-metastatic PCa
+Histologically or cytologically confirmed cancer (hematologic or solid) who are not currently on hospice care
+Non-metastatic histologically confirmed primary invasive breast carcinoma
+Histologically confirmed resectable or borderline resectable pancreatic adenocarcinoma; pathology report form
+Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas
+Patients with a histologically or cytologically confirmed solid tumor or aggressive NHL who are refractory to or have exhausted all available therapies
+Histologically or cytologically confirmed adenocarcinoma of the pancreas that has not been previously treated in the metastatic setting
+Patients with stage IV or recurrent/metastatic histologically or cytologically confirmed non-squamous NSCLC
+Adult patients > 18 years with histologically or cytologically confirmed Peripheral T-cell lymphoma (PTCL)
+Histologically confirmed peritoneal carcinomatosis from appendiceal, colorectal, ovarian, or primary mesothelioma, with no systemic metastases
+Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC
+Memorial Sloan Kettering (MSK) histologically confirmed metastatic breast cancer
+Patients must have histologically or cytologically confirmed colorectal or pancreatic carcinoma
+Patient must have histologically or cytologically confirmed small cell lung cancer; patients with either limited or extensive stage disease are eligible
+Histological or cytologically confirmed prostate adenocarcinoma
+Histologically-confirmed high grade dysplasia (HGD), cancer, or polyp burden that is not quantifiable
+Naïve or non-naïve patient with histologically, and/or cytologically (or imaging in the case of brain tumors) confirmed malignant disease.
+Cytologically or histologically confirmed of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancer
+Histologically-confirmed chronic multifocal atrophic gastritis (MAG) and/or gastric intestinal metaplasia (GIM)
+Age >= 18 years, with histologically confirmed diagnosis of Barrett's Esophagus without dysplasia
+Men and women, 18 years or older, with histologically or cytologically-confirmed either:
+Histologically confirmed adenocarcinoma of the pancreas
+Participants must have histologically confirmed diagnosis of a solid tumor for which no curative therapy exists
+A histologically or cytologically confirmed ovarian, breast, non-small cell lung, melanoma, gastric/GEJ/esophageal or other type of advanced cancer that is metastatic, unresectable, or recurrent and for which weekly paclitaxel is an acceptable therapeutic option.
+Histologically proven diagnosis of GBM.
+Histologically or cytologically confirmed breast cancer
+Patients who are scheduled to receive a taxane-based regimen for a histologically confirmed solid tumor that is:
+Histologically confirmed metastatic breast cancer
+Histologically confirmed adenocarcinoma of the prostate.
+Histologically-confirmed (confirmation done at Memorial Sloan-Kettering Cancer Center [MSKCC]) metastatic adenocarcinoma of the breast
+Participants must have evidence of metastatic cancer to the brain for cohort A or histologically confirmed glioblastoma (GBM) for cohorts B and C
+Confirmed diagnosis of adenocarcinoma lung cancer OR,
+Histologically confirmed prostate cancer
+Pathologically (histologically or cytologically) proven diagnosis of cervical, vulvar, esophageal and anal canal cancer
+Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma
+Have a histologically-confirmed diagnosis of breast cancer
+Patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary and its respective variants)
+Histologically confirmed adenocarcinoma of the prostate
+Histologically confirmed cT0-4, N1 breast cancer
+Patients must have histologically or cytologically confirmed diagnosis of unresectable, stage III or metastatic melanoma
+Histologically confirmed adenocarcinoma of the prostate
+History of histologically confirmed melanoma as assessed per medical record review
+Patients must have histologically or cytologically confirmed prostate cancer confirmed by the Laboratory of Pathology, National Cancer Institute (NCI) or Pathology Department at Walter Reed Bethesda
+Patients must have histologically confirmed primary or metastatic cancer; if biopsies were performed at an outside facility, the histology must be reviewed and confirmed by the Department of Pathology at the City of Hope
+Histologically confirmed adenocarcinoma of the prostate; patients with small cell, neuroendocrine, and transitional cell carcinomas are not eligible
+Participants must have histologically or cytologically confirmed human epidermal growth factor receptor 2 (HER2) negative invasive breast adenocarcinoma
+Patients must have histologically or cytologically confirmed prostate cancer; the outside pathology report is acceptable for study entry; every effort will be made to acquire the outside pathology slides to be confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)
+Patients must have a history of histologically or cytologically confirmed prostate cancer; the outside pathology report is acceptable for study entry; every effort will be made to acquire the outside pathology slides to be confirmed by the Laboratory of Pathology, NCI
+Patients with history of histologically-confirmed solid malignancy and/or lymphoma (histology confirmed by Memorial Sloan-Kettering Cancer Center (MSKCC) Department of Pathology)
+Histologically-confirmed prostate cancer
+Participants must have histologically or cytologically confirmed invasive or in-situ carcinoma of the breast
+Patients with histologically confirmed prostate cancer
+Histologically confirmed diagnosis of colorectal adenocarcinoma
+Pathologically (histologically or cytologically) proven diagnosis of carcinoma
+Histologically confirmed primary adenocarcinoma of the prostate
+Have histologically or cytologically confirmed small bowel carcinoid tumor
+Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology
+Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma
+Participants must have histologically confirmed prostate cancer
+Histologically confirmed diagnosis of prostate cancer
+Has histologically or cytologically documented adenocarcinoma NSCLC
+Participants must have histologically confirmed intracranial meningioma, grade II-III, that has recurred or progressed after previous treatment
+For Parts A and B: Has histologically or cytologically confirmed metastatic solid tumor
+a primary brain tumor that has been histologically confirmed
+Patients must have either \r\n* 1) histologically/cytologically-confirmed borderline resectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care, or \r\n* 2) histologically/cytologically-confirmed locally advanced unresectable pancreatic cancer and be prescribed neoadjuvant gemcitabine-plus-Abraxane as part of their standard of care
+A diagnosis of histopathologically confirmed rectal adenocarcinoma
+Mediastinal nodal metastases (N2) disease must be confirmed histologically
+Histologically confirmed adenocarcinoma of the prostate
+History of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).
+Subject must be expected to undergo a clinically indicated surgical resection of histologically confirmed or suspected pancreatic ductal adenocarcinoma
+Patients with histologically confirmed prostate cancer
+Patients must have histologically confirmed glioblastoma/gliosarcoma confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)
+Patients must have histologically-confirmed HNSCC with surgically resectable disease
+Patients must have histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease.
+Patients must have histologically or cytologically confirmed prostate cancer confirmed by the Laboratory of Pathology, National Cancer Institute (NCI) or Pathology Department of the Walter Reed National Military Medical Center
+Histologically or cytologically confirmed pancreatic ductal adenocarcinoma
+Histologically or cytologically confirmed primary breast cancer.
+Subjects must have histologically or cytologically confirmed esophageal, colorectal or pancreatic adenocarcinoma (inclusive of high grade dysplasia) on a biopsy prior to surgery and must be scheduled for surgical resection, inclusive of endoscopic mucosal resection, of the primary tumor. Subjects at any cancer stage will be enrolled.
+Histologically confirmed:
+Histologically or cytologically-confirmed advanced or metastatic GIST with a D842V mutation in the PDGFRA gene as determined by central laboratory testing
+Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx is allowed, but these participants will not be included as response-evaluable participants for efficacy analysis of HNSCC.
+Age ? 18 years with histologically- or cytologically-confirmed, extensive-stage, chemotherapy-naïve SCLC
+Histologically confirmed adenocarcinoma of the prostate gland by needle core samples with assigned Gleason score
+Histologically or cytologically confirmed metastatic NSCLC including recurrent disease
+Patients with a histologically confirmed solid tumor:
+Participants must have histologically or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes: